Kun Liu

USPTO Granted Patents = 48 (Patent Applications = 4)

CIPO Patents = 3 (Patent Applications = 10)

EPO Patents = 26 (Patent Applications = 20)

Average Co-Inventor Count = 8.2

ph-index = 8

Forward Citations = 210(Granted Patents)

Location History:

Edison, NJ (US) (2000 - 2016)
Rahway, NJ (US) (2015 - 2017)
Boston, MA (US) (2015 - 2021)
Needham, MA (US) (2015 - 2024)

Company Filing History:

39 out of 2,405

Merck Sharp + Dohme Corp.

Alectos Therapeutics Inc.

Simon Fraser University

7. 2 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 2000-2025

where 'Filed Patents' based on already Granted Patents

48 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12414952 - Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use (2025-09-16),

2. 12275729 - Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2025-04-14),

3. 12263171 - 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use (2025-04-01),

4. 12060357 - 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use (2024-08-13),

5. 11319283 - Substituted cyclobutylbenzene compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2022-05-03),

6. 11312719 - 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use (2022-04-26),

7. 11111232 - Substituted cyclobutylpyridine and cyclobutylpyrimidine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2021-09-07),

8. 11096930 - Substituted imidazopyridine compounds as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan-2,3-dioxygenase (2021-08-24),

9. 11053243 - Inhibitors of hepatitis C virus replication (2021-07-06),

10. 11034661 - Substituted N'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase IDO inhibitors (2021-06-15),

11. 10995085 - Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2021-05-04),

12. 10988487 - Substituted n'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2021-04-27),

13. 10927086 - Substituted sulfoximine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2021-02-23),

14. 10745364 - Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease (2020-08-18),

15. 10689369 - Substituted indazole compounds as RORgammaT inhibitors and uses thereof (2020-06-23),

Title: The Innovative Contributions of Kun Liu in Pharmaceutical Patents

Introduction: Kun Liu, a prolific inventor based in Needham, MA, has made significant strides in the field of pharmaceutical innovations, holding an impressive total of 45 patents. His work focuses on developing novel compounds and methods that target various receptor mechanisms, showcasing his commitment to advancing medical science.

Latest Patents: Among Kun Liu's most recent patents are the advancements in 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists. This particular patent outlines the structural formula of new compounds, their pharmaceutical compositions, and their application in treating conditions mediated by adenosine receptors. Additionally, his work on substituted cyclobutylbenzene compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors is noteworthy. This patent discusses the potential pharmaceutical uses of a specific compound for the treatment or prevention of IDO-associated diseases, along with detailed compositions for the same.

Career Highlights: Liu's career features prominent roles in leading pharmaceutical companies like Merck Sharp & Dohme Corporation and Merck & Company, Inc. His tenure in these organizations has enabled him to contribute significantly to the development of groundbreaking medical therapies and compounds.

Collaborations: Throughout his career, Kun Liu has collaborated with esteemed colleagues, including Hongjun Zhang and Nunzio Sciammetta. These partnerships have facilitated the exchange of ideas that drive innovation and enhance the prospect of successful pharmaceutical interventions.

Conclusion: Kun Liu's portfolio of 45 patents underscores his dedication to innovation in the pharmaceutical field. His groundbreaking work, particularly in the area of receptor antagonism and enzyme inhibition, not only reflects his personal commitment to improving healthcare but also contributes to the broader scientific community striving to find effective treatments for various medical conditions.

This text is generated by artificial intelligence and may not be accurate.